A major pharmaceutical company has initiated legal proceedings against Hims & Hers, accusing the company of violating the U.S. patent on semaglutide. Bloomberg posted on X, highlighting the ongoing legal battle and inviting readers to engage with the latest edition of Pointed, Bloomberg’s weekly news quiz for risk-takers. The lawsuit underscores the competitive nature of the pharmaceutical industry, where patent rights are fiercely protected to maintain market advantage. Semaglutide, a medication used for treating certain medical conditions, is at the center of this dispute, reflecting the high stakes involved in pharmaceutical patents. The outcome of this lawsuit could have significant implications for both companies involved and the broader industry.